Hypothesis: Mutations and Immunosurveillance in Obesity-Associated Colorectal Cancer.

BMI Colon cancer cell signaling mutations obesity

Journal

Journal of Cancer
ISSN: 1837-9664
Titre abrégé: J Cancer
Pays: Australia
ID NLM: 101535920

Informations de publication

Date de publication:
2022
Historique:
received: 11 06 2022
accepted: 27 07 2022
entrez: 1 9 2022
pubmed: 2 9 2022
medline: 2 9 2022
Statut: epublish

Résumé

Tumorigenesis typically requires the accumulation of several driver gene mutations; therefore, there is a mutation threshold for the completion of the neoplastic process. Obesity increases the risk of cancer, and we have proposed that one mechanism whereby obesity raises the risk of microsatellite stable (MSS) colon cancer is by decreasing the mutation threshold. Therefore, obese MSS colon cancer patients should exhibit fewer driver gene mutations compared to normal body-mass index (BMI) patients. Our hypothesis is supported by results from analyses of The Cancer Genome Atlas (TCGA) data, which revealed that cancer genomes of obese MSS colon patients exhibit both fewer somatic mutations and fewer driver gene mutations. These findings could be explained by the high levels of obesity-associated cytokines and factors, the signaling pathways of which substitute for the additional driver gene mutations detected in normal-weight MSS colon cancer patients. Therefore, obesity-induced aberrant cell signaling might cooperate with initiating driver gene mutations to promote neoplastic development. Consistent with this possibility, we observed a lower number of

Identifiants

pubmed: 36046651
doi: 10.7150/jca.76052
pii: jcav13p3044
pmc: PMC9414022
doi:

Types de publication

Journal Article

Langues

eng

Pagination

3044-3050

Informations de copyright

© The author(s).

Déclaration de conflit d'intérêts

Competing Interests: The authors have declared that no competing interest exists.

Références

Nature. 2019 Jul;571(7766):570-575
pubmed: 31243362
JAMA. 2014 Feb 26;311(8):806-14
pubmed: 24570244
Front Biosci (Elite Ed). 2013 Jan 01;5(1):61-77
pubmed: 23276970
BMC Res Notes. 2009 Jun 15;2:105
pubmed: 19527493
Curr Opin Immunol. 2016 Apr;39:44-51
pubmed: 26796069
J Cancer. 2021 Sep 24;12(22):6825-6834
pubmed: 34659571
J Nutr Biochem. 2020 Mar;77:108302
pubmed: 31825818
Sci Immunol. 2018 May 18;3(23):
pubmed: 29776993
Lancet Public Health. 2019 Mar;4(3):e137-e147
pubmed: 30733056
CA Cancer J Clin. 2021 Nov;71(6):527-546
pubmed: 34383300
Gut. 2013 Jun;62(6):933-47
pubmed: 23481261
Curr Opin Immunol. 2011 Apr;23(2):265-71
pubmed: 21277761
Cell. 2017 Nov 30;171(6):1272-1283.e15
pubmed: 29107334
Nat Neurosci. 2020 Jul;23(7):842-853
pubmed: 32424282
World J Gastroenterol. 2017 Aug 28;23(32):5829-5835
pubmed: 28932075
Oncoimmunology. 2013 Nov 1;2(11):e26491
pubmed: 24482746
Expert Opin Biol Ther. 2021 Oct;21(10):1347-1357
pubmed: 34030532
Hum Hered. 1989;39(3):156-64
pubmed: 2591979
F1000Res. 2020 Sep 28;9:
pubmed: 33014341
Cancer Immunol Immunother. 2022 Apr;71(4):819-827
pubmed: 34417841
Curr Opin Immunol. 2018 Apr;51:68-75
pubmed: 29544121
J Cancer. 2015 Jul 15;6(9):825-31
pubmed: 26284133
JAMA Surg. 2015 Jan;150(1):17-22
pubmed: 25372703
Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):133-7
pubmed: 15668486
J Pharmacol Sci. 2007 Oct;105(2):129-32
pubmed: 17928742
Curr Opin Gastroenterol. 2010 Jan;26(1):5-11
pubmed: 19901833
Blood. 2009 Oct 29;114(18):3803-12
pubmed: 19721009
Oncologist. 2010;15(6):556-65
pubmed: 20507889

Auteurs

Darina Lazarova (D)

Department of Medical Education, Geisinger Commonwealth School of Medicine, 525 Pine Street, Scranton, PA 18509, USA.

Michael Bordonaro (M)

Department of Medical Education, Geisinger Commonwealth School of Medicine, 525 Pine Street, Scranton, PA 18509, USA.

Classifications MeSH